



PATENT

Case Docket No. LATTA.002C3

Date: March 4, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Paul P. Latta
Appl. No. : 10/660,924
Filed : September 12, 2003
For : INDUCTION OF
IMMUNOLOGICAL
TOLERANCE
Examiner : Unknown
Group Art Unit : 1632

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 4, 2004

(Date)

Marina L. Gordey, Reg. No. 52,950


TRANSMITTAL LETTER


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with fifty (50) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.


Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580



INFORMATION DISCLOSURE STATEMENT

Applicant : Paul P. Latta
App. No. : 10/660,924
Filed : September 12, 2003
For : INDUCTION OF IMMUNOLOGICAL
TOLERANCE
Examiner : Unknown
Group Art Unit : 1632

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is form PTO-1449 listing 50 references that are of record in U.S. patent application No. 09/226,742, filed January 7, 1999, which is the parent of this Continuation application, and is relied upon for an earlier filing date under 35 U.S.C. § 120. Copies of the references are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 3, 2004

By: 
Marina L. Gordey
Registration No. 52,950
Agent of Record
Customer No. 20,995
(805) 547-5580

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
LATTA.002C3APPLICATION NO.
10/660,924INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(SEE SEVERAL SHEETS IF NECESSARY)

APPLICANT
PAUL P. LATTAFILING DATE
September 12, 2003GROUP
1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
	1.	4,298,002	11/03/81	RONEL et al.			
	2.	4,353,888	10/12/82	SEFTON			
	3.	4,378,016	03/29/83	LOEB			
	4.	4,673,566	06/16/87	GOOSEN et al.			
	5.	4,689,293	08/25/87	GOOSEN et al.			
	6.	4,696,286	09/29/87	COCHRUM			
	7.	4,806,355	02/21/89	GOOSEN et al.			
	8.	4,892,538	01/09/90	AEBISCHER et al.			
	9.	4,902,295	02/20/90	WALTHALL et al.			
	10.	4,997,443	03/05/91	WALTHALL et al.			
	11.	5,182,111	01/26/93	AEBISCHER et al.			
	12.	5,262,044	11/16/93	BAE et al.			
	13.	5,290,684	03/01/94	KELLY			
	14.	5,529,914	06/25/96	HUBBELL et al.			
	15.	5,425,764	06/20/95	FOURNIER et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	16.	A2 0,147,939	10/07/85	EPO				
	17.	A1 2,034,641	28/05/92	CANADA				
	18.	WO 92/19195	12/11/92	PCT				
	19.	WO 95/03062	02/02/95	PCT				
	20.	0 536 807 A1	04/02/87	EP				

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	21.	Aebischer, P. et al., "LONG-TERM CROSS-SPECIES BRAIN TRANSPLANTATION OF A POLYMER-ENCAPSULATED DOPAMINE-SECRETING CELL LINE" <i>Experimental Neurology</i> (1991) 111:269-275
	22.	Aebischer, P. et al., "TRANSPLANTATION OF POLYMER ENCAPSULATED NEUROTRANSMITTER SECRETING CELLS: EFFECT OF THE ENCAPSULATION TECHNIQUE" <i>Journal of Biomechanical Engineering</i> (1991) 113:178-183

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
LATTA.002C3APPLICATION NO.
10/660,924INFORMATION DISCLOSURE STATEMENT
BY APPLICANTAPPLICANT
PAUL P. LATTAFILING DATE
September 12, 2003GROUP
1632

(USE SEVERAL SHEETS IF NECESSARY)



EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	23.	Bartlett, S.T. et al., "COMPOSITE KIDNEY-ISLET TRANSPLANTATION PREVENTS RECURRENT AUTOIMMUNE BETA-CELL DESTRUCTION" <i>Surgery</i> (1993) 114:211-217
	24.	Buchser, et al., "IMMUNOISOLATED XENOGENIC CHROMAFFIN CELL THERAPY FOR CHRONIC PAIN. INITIAL CLINICAL EXPERIENCE" <i>Anesthesiol.</i> , (1996) 85:1005-1012
	25.	Chicheportiche, D. et al., "IN VITRO KINETICS OF INSULIN RELEASE BY MICROENCAPSULATED RAT ISLETS: EFFECT OF THE SIZE OF THE MICROCAPSULES" <i>Diabetologia</i> (1988) 31:54-57
	26.	Colton, C.K. (1995), "IMPLANTABLE BIOHYBRID ARTIFICIAL ORGANS" <i>Cell Transplantation</i> 4(4):415-436.
	27.	Dixit, V. et al., "A MORPHOLOGICAL AND FUNCTIONAL EVALUATION OF TRANSPLANTED ISOLATED ENCAPSULATED HEPATOCYTES FOLLOWING LONG-TERM TRANSPLANTATION IN GUNN RATS" <i>Biomat. Art. Cells & Immob. Biotech.</i> (1993) 21(2):119-133
	28.	Gao, E-K et al., "T CELL CONTACT WITH Ia ANTIGENS ON NONHEMOPOIETIC CELLS IN VIVO CAN LEAD TO IMMUNITY RATHER THAN TOLERANCE" <i>J. Exp. Med.</i> (1991) 174:435-446
	29.	Gilbert, J.C. et al., "CELL TRANSPLANTATION OF GENETICALLY ALTERED CELLS ON BIODEGRADABLE POLYMER SCAFFOLDS IN SYNGENEIC RATS" <i>Transplantation</i> (1993) 56(2):423-427
	30.	Hansan, et al., "EVIDENCE THAT LONG-TERM SURVIVAL OF CONCORDANT XENOGRAFTS IS ACHIEVED BY INHIBITION OF ANTISPECIES ANTIBODY PRODUCTION" <i>Transplantation</i> , (1992) 54:408-413
	31.	Hill, R.S. et al., "MEMBRANE ENCAPSULATED ISLETS IMPLANTED IN EPIDIDYMAL FAT PADS CORRECT DIABETES IN RATS" <i>Cell Transplantation</i> (1992) 1(213):132 p. 168
	32.	Hoffman, D. et al., "TRANSPLANTATION OF A POLYMER-ENCAPSULATED CELL LINE GENETICALLY ENGINEERED TO RELEASE NGF" <i>Experimental Neurology</i> (1993) 122:100-106
	33.	Husby, s. et al., "ORAL TOLERANCE IN HUMANS. T CELL BUT NOT B CELL TOLERANCE AFTER ANTIGEN FEEDING" <i>J. Immunol.</i> , (1994) 152:4663-4670
	34.	Kneteman, N.M. et al., "ISOLATION AND CRYOPRESERVATION OF HUMAN PANCREATIC ISLETS" <i>Transplantation Proceedings</i> (1986) XVIII(1):182-185
	35.	Lacy, P.E. et al., "MAINTENANCE OF NORMOGLYCEMIA IN DIABETIC MICE BY SUBCUTANEOUS XENOGRAFTS OF ENCAPSULATED ISLETS" <i>Science</i> (1991) 254:1782-1784
	36.	Lanza, R.P. et al., "XENOTRANSPLANTATION OF CANINE, BOVINE, AND PORCINE ISLET" <i>PNAS USA</i> (1991) 88:11100-11104.
	37.	Lanza, R.P. et al., "TRANSPLANTATION OF ENCAPSULATED CANINE ISLETS INTO SPONTANEOUSLY" <i>Endocrinology</i> (1992), 131(2):637-642
	38.	Liu, H. et al., "EXPRESSION OF HUMAN FACTOR IX BY MICROENCAPSULATED RECOMBINANT FIBROBLASTS" <i>Human Gene Therapy</i> (1993) 4:291-301
	39.	Lum, Z. et al., "PROLONGED REVERSAL OF DIABETIC STATE IN NOD MICE BY XENOGRAFTS OF MICROENCAPSULATED RAT ISLETS" <i>Diabetes</i> (1991) 40:1511-1516
	40.	Nossal, G.J.V. "IMMUNOLOGICAL TOLERANCE" in: <i>Fundamental Immunology</i> , Second Edition, edited by W.E. Paul, Raven Press, New York, pp 571-585 (1989)
	41.	Osband, ME et al., "PROBLEMS IN THE INVESTIGATIONAL STUDY AND CLINICAL USE OF CANCER IMMUNOTHERAPY" <i>Immunological Today</i> , (1990) 11(6):193-195
	42.	Posselt, A.M. et al., "INDUCTION OF DONOR-SPECIFIC UNRESPONSIVENESS BY INTRATHYMIC ISLET TRANSPLANTATION" <i>Science</i> (1990) 249:1293-1295
	43.	Posselt, A.M. et al., "INTRATHYMIC ISLET TRANSPLANTATION IN THE SPONTANEOUSLY DIABETIC BB RAT" <i>Ann. Surg.</i> (1991) 214(4):363-373

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (SEE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. LATTA.002C3	APPLICATION NO. 10/660,924
	APPLICANT PAUL P. LATTA	
	FILING DATE September 12, 2003	GROUP 1632

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	44.	Ricordi, C. et al., "AUTOMATED METHOD FOR ISOLATION OF HUMAN PANCREATIC ISLETS" <i>Diabetes</i> (1988) 37:413-420
	45.	Soon-Shiong, P. et al., "PREVENTION OF CTL AND NK CELL-MEDIATED CYTOTOXICITY BY MICROENCAPSULATION" <i>Hormone Metab. Res.</i> (1990) 25 (suppl.): 215-219
	46.	Sullivan, S.J. et al., "BIOHYBRID ARTIFICIAL PANCREAS: LONG-TERM IMPLANTATION STUDIES IN DIABETIC, PANCREATECTOMIZED DOGS" <i>Science</i> (1991) 252:718-720
	47.	Tai, I.T. et al., "MICROENCAPSULATION OF RECOMBINANT CELLS: A NEW DELIVERY SYSTEM FOR GENE THERAPY" <i>FASEB J.</i> (1993) 7:1061-1069
	48.	Tueveson, G et al., "NEW IMMUNOSUPPRESSANTS: TESTING AND DEVELOPMENT IN ANIMAL MODELS AND THE CLINIC: WITH SPECIAL REFERENCE TO DSG" <i>Immunological Reviews</i> , (1993)136:99-109
	49.	Tresco, P.A. et al., "POLYMER ENCAPSULATED NEUROTRANSMITTER SECRETING CELLS POTENTIAL TREATMENT FOR PARKINSON'S DISEASE" <i>ASAIO Journal</i> (1992) 38:17-23
	50.	Wong, H. et al., "THE MICROENCAPSULATION OF CELLS WITHIN ALGINATE POLY-L-LYSINE MICROCAPSULES PREPARED WITH THE STANDARD SINGLE STEP DROP TECHNIQUE: HISTOLOGICALLY IDENTIFIED MEMBRANE IMPERFECTIONS AND THE ASSOCIATED GRAFT REJECTION" <i>Biomat., Art. Cells & Immob. Biotech.</i> (1991) 19(4):675-686

O:\DOCS\MXG\MXG-4621.DOC:sh
021304

EXAMINER	DATE CONSIDERED
*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	